EVERFI from Blackbaud’s Prescription Drug Safety Course Certified as Meeting Rigorous ESSA Evidence Standards

Recognition validates that the course has a positive impact on students’ knowledge of safe prescription drug use and potential future actions 

Charleston, SC (May 7, 2024) – EVERFI® from Blackbaud®, the leader in powering social impact through education, today announced that its program, Prescription Drug Safety: Know the truth, has been certified as meeting the evidence-based standards outlined in the Every Student Succeeds Act (ESSA), aligning with Level III certification for “Promising Evidence.” This certification demonstrates that usage of the course correlates with students’ personal responsibility, perceived social norms, knowledge of safe prescription drug use, and potential future actions.

The ESSA certification was awarded through LearnPlatform by Instructure, following an extensive review of the research study, “Promoting Prescription Drug Safety Skills in School: Evaluating the Effectiveness of a Technology-Based Curriculum.” The research study, conducted by Lynch Research Associates, found that compared to a control group of students, students who took EVERFI’s prescription drug safety course saw:  

• Significant growth in personal responsibility for helping to prevent prescription drug abuse or misuse with others in their community  
• More accurate perceptions of social norms for prescription drug abuse, misuse, or refusal among peers  
• Increased knowledge of prescription drug-related topics including addiction, safe use of prescriptions, and refusal skills  
• Lower likelihood of engaging in future actions related to prescription drug abuse or misuse  
• Improved refusal skills for rejecting offers of prescription drugs in situations

Prescription drug misuse among youth aged 12-18 remains high in the United States with The National Institute on Drug Abuse indicating that approximately 2,000 teens abuse prescription drugs every single day and upwards of 3 million youth aged 12-17 admitted to abusing prescription drugs at least once in their lifetime. Public health experts and medical providers have been increasingly calling for effective, evidence-based prescription drug misuse prevention and intervention programming that reaches large numbers of youth who may be exposed to opportunities to engage in non-medical prescription drug use.

“The statistics around prescription drug misuse and abuse are startling and we cannot deny that as a country, we have reached a point of crisis and urgent action is needed,” said Alice Lee, senior vice president, K-12 implementation, EVERFI from Blackbaud. “One of the clearest ways to reach the student population with potentially lifesaving information is through our K-12 school system. We work closely with leading experts to design and develop our courses and with school districts to bring them to students nationwide. Certifications like this are important to validate the program and allow us to bring this education to more students.” 

Schools and school districts are increasingly encouraged to use programs and tools that have been proven, through rigorously designed research studies, to positively impact student outcomes. The ESSA Levels of Evidence provide an easy-to-interpret framework for identifying what programs work. With LearnPlatform, EVERFI has a respected third-party evidence partner that solidifies the company’s commitment to demonstrating the impact of its programs for students. EVERFI is committed to continuing to strengthen its library of evidence and bring high-quality evidence-based programs to educators in every classroom.

Prescription Drug Safety: Know the truth is a free digital course that guides teachers and educates youth about the dangers associated with misusing prescription medications. Through real-world scenarios, students can recognize the impact prescription drug misuse can have on their physical and mental health, relationships, and future. They also learn how to support others in situations involving prescription drug misuse and overdose.

Since its launch in 2017, nearly 1.3 million students have actively engaged with the curriculum, and more than 7,000 schools have used the course.

For more information or to sign up for the Prescription Drug Safety: Know the truth course, visit https://everfi.com/courses/k-12/prescription-drug-safety-high-school/.  

About EVERFI from Blackbaud
EVERFI® from Blackbaud® (NASDAQ: BLKB) is an international technology company driving social impact through education to address the most challenging issues affecting society ranging from financial wellness to mental health to workplace conduct and other critical topics. Founded in 2008, EVERFI’s Impact-as-a-Service™ solution and digital educational content have reached more than 45 million learners globally. In 2020, the company was recognized as one of the World’s Most Innovative Companies by Fast Company and was featured on Fortune Magazine’s Impact 20 List. The company was also named to the 2021 GSV EdTech 150, a list of the most transformative growth companies in digital learning. Blackbaud acquired EVERFI in December 2021. To learn more about EVERFI, please visit everfi.com or follow us on Facebook, Instagram, LinkedIn, or X/Twitter @EVERFI. 

Media Inquiries
Jennifer Edgerly 
EVERFI from Blackbaud
jedgerly@everfi.com

Blackbaud Forward-looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this news release are forward-looking statements that involve a number of risks and uncertainties, including statements regarding expected benefits of products and product features. Although Blackbaud attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors that could cause results to differ materially include the following: general economic risks; uncertainty regarding increased business and renewals from existing customers; continued success in sales growth; management of integration of acquired companies and other risks associated with acquisitions; risks associated with successful implementation of multiple integrated software products; the ability to attract and retain key personnel; risks associated with management of growth; lengthy sales and implementation cycles, particularly in larger organization; technological changes that make our products and services less competitive; and the other risk factors set forth from time to time in the SEC filings for Blackbaud, copies of which are available free of charge at the SEC’s website at www.sec.gov or upon request from Blackbaud’s investor relations department. All Blackbaud product names appearing herein are trademarks or registered trademarks of Blackbaud, Inc.